Research peptide news, October 2026: the HHS compounding policy, vendor closures and what changed

Published November 6, 2026. This is a dated record of what happened in the U.S. research-peptide space during October 2026: one federal policy, the step that preceded it, two vendor closures and a successor claim, and a milestone in public third-party testing. Each item gives a date and cites a page opened while writing. For the 2025 to September 2026 background (FDA's category changes, the July advisory-committee votes and the August warning letters), see our 2027 timeline; this page does not repeat it.

Research peptide news, October 2026 at a glance#

The HHS interim peptide compounding policy (October 28, 2026)#

The largest regulatory event of the month was the HHS "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." It states that HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician that compounds one of six peptides listed in its Appendix A (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500) while meeting ten conditions.^[1] These are the six that FDA's Pharmacy Compounding Advisory Committee voted to recommend in July 2026.^[5]

Among the ten conditions: the bulk substance must come from an FDA-registered facility with a valid certificate of analysis covering identity, purity, potency and freedom from harmful contaminants; the original manufacturer must be FDA-registered, follow current good manufacturing practice and be named on that certificate; compounders must report serious adverse events and quality problems to FDA's MedWatch program; each product may contain only one Appendix A ingredient; and the label must read "This is a compounded drug product. Not for resale."^[1][3] AJMC noted that the policy came from the Office of the Secretary rather than from FDA.^[4]

The policy is interim and conditional. The Federal Register notice says it "does not establish any rights for any person and is not binding on HHS or the public," that HHS "may revisit application of this interim policy" if a safety signal or product-quality issue arises, and that future rulemaking "may propose adding some or all of these peptides to the 503A bulks list."^[2] RAPS reported that it remains in effect until FDA develops that list through rulemaking.^[5] It is not an FDA approval of any of the six.

What the policy says about research-use-only products#

The policy document names research-use-only products directly: it describes "research-use-only peptides supplied by foreign manufacturers" as a safety risk and says the policy is meant to discourage their continued, widespread use.^[1][16] It does not extend to research suppliers. BakerHostetler's summary states that the policy "does not apply to outsourcing facilities operating under Section 503B or to products sold as research chemicals or dietary supplements."^[6] In other words, the October policy concerns licensed compounders; it did not change the position of a research-use-only reagent sold for laboratory work.

The step before it: the October 14 OIRA submission#

Two weeks earlier, Frier Levitt reported that a proposed "Interim Access Policy for Compounding Using Certain Peptides" had been "submitted to the Office of Information and Regulatory Affairs for review on October 14, 2026," and that the public filing did not identify the peptides or the conditions.^[8] The American Med Spa Association reported the same submission on October 16.^[9] AJMC later reported that four outside groups met with White House reviewers before the policy was released.^[4]

Reactions on record#

Responses were divided, and we report them without taking a side. RAPS quoted Public Citizen's Robert Steinbrook urging HHS to rescind the policy: "All peptide substances should go through the standard FDA approval process for new drugs."^[5] It also quoted researchers at the Center for Science in the Public Interest on the earlier committee recommendations.^[5] AJMC reported that the Partnership for Safe Medicines asked FDA to disregard the advisory-committee vote, and that a compounding-industry figure said states may not follow the federal government in relaxing rules.^[4] HHS's stated rationale, as RAPS and McDermott reported it, was to offer "a more controlled alternative" to research-use-only peptides from foreign manufacturers.^[5][16]

FDA actions in October 2026: what happened and what did not#

We found no new FDA warning letter to an online research-peptide seller dated October 2026. The most recent such letters we could confirm were dated August 24, 2026, as reported in September.^[11] The background on those letters, and FDA's reasoning that a research-use-only label does not settle intended use, is in our 2027 timeline. Frier Levitt's October 14 note repeats the same principle: FDA judges intended use from the totality of the circumstances, including labeling, advertising and distribution practices.^[8]

FDA had also not completed the rulemaking that would place any of the six peptides on the 503A bulks list; the HHS policy exists because that process is unfinished.^[5] The committee's next peptide meeting remains listed by FDA as taking place "before the end of February 2027" to discuss LL-37, GHK-Cu, dihexa acetate, melanotan II and PEG-MGF, with time and location still to be scheduled; the page was last updated April 15, 2026.^[10]

Research peptide vendor closures in October 2026#

Two closures touched October. Chameleon Peptides ceased operations on September 27, 2026, and its storefront now reads "Chameleon Peptides is Closed."^[12][13] The Peptide Catalog reported a farewell email on October 1 and quoted the closure page: "Existing customers can sign in to view order history and lab reports." It also reported, citing a customer email documented by CompoundReview, that the company said its buyer attestations were "no longer sufficient in the current compliance environment."^[12] We could not open the email or CompoundReview's page ourselves, so that reason is reported here only as attributed.

Soma Chems' storefront began showing that it was no longer accepting new orders in mid-October, after a close-out sale that ended October 12. Our Soma Chems page records the notice's exact wording as we observed it on October 13, 2026. On October 28, a company calling itself Soma Chems US issued a paid press release stating that "the original storefront states that it is no longer accepting new orders," that it gives no reason or reopening date, and that Soma Chems US "does not represent itself as a relocation or continuation of the original business."^[14] We report the release as the issuer's own statement and have not verified any relationship between the two.

Our dated list of 2026 vendor closures records each closure we could source this year, with what each vendor's notice said and what customers were told.

Testing ecosystem: Finnrick passes 12,700 public tests#

Finnrick, which publishes third-party laboratory tests of research-peptide vials, showed a running total of 12,729 tests on its homepage, last updated October 29, 2026; its page description reported 302 new entries in the past month.^[15] Its per-compound leaderboard showed BPC-157 at 943 tests across 149 vendors as of October 21, 2026.^[15] The earlier milestone (more than 10,000 tests, reported in May 2026) is in our 2027 timeline. Our guide to reading a public test listing explains what a single listing does and does not show.

What to watch in November 2026#

• November 13, 2026: the comment period on the HHS interim policy closes.^[3]
• FDA rulemaking on the 503A bulks list: the HHS policy stays in effect until FDA develops the list through rulemaking; we found no proposed rule as of this writing.^[5]
• The next advisory-committee meeting: FDA's page still shows no date.^[10]
• Successor and lookalike claims after the October closures: treat any site using a closed vendor's name as unverified until the closed vendor's own domain says otherwise.

This page makes no prediction about any of these. It will be followed by a November roundup with the same format.

How this roundup is compiled#

Every item above was checked against a page opened on November 6, 2026: the HHS policy document, the Federal Register public-inspection copy, FDA's committee page, and dated reports from law firms, trade press and vendor-closure observers. Where only a secondary report exists, the item says whose report it is. Pages that carry affiliate links are cited only for dated observations. Renuvia Labs is a research-peptide supplier in Dallas, Texas; we have no affiliation with any vendor named here. If you have a dated primary source that corrects anything on this page, email support@renuviaus.com.